ObsEva SA

ObsEva Presents Clinical Data on Oral GnRH Antagonist

ObsEva Presents Clinical Data on Oral GnRH Antagonist

-Data featured in two oral presentations at the 8th Society of Endometriosis and Uterine Disorders Congress and a poster presentation at the International Society of Gynecological endocrinology 20th World Congress† GENEVA, Switzerland May 252022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced the …

ObsEva Presents Clinical Data on Oral GnRH Antagonist Read More »

Investegate |ObsEva SA Announcements |  ObsEva SA: ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix at Multiple Congresses

Investegate |ObsEva SA Announcements | ObsEva SA: ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix at Multiple Congresses

ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix at Multiple Congresses -Data featured in two oral presentations at the 8th Society of Endometriosis and Uterine Disorders Congress and a poster presentation at the International Society of Gynecological endocrinology 20 th World Congress † GENEVA, Switzerland May 2 5 2022 – ObsEva SA (NASDAQ: OBSV; …

Investegate |ObsEva SA Announcements | ObsEva SA: ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix at Multiple Congresses Read More »